Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imatinib
Drug ID BADD_D01136
Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status Prescription; Discontinued
ATC Code L01EA01
DrugBank ID DB00619
KEGG ID D08066
MeSH ID D000068877
PubChem ID 5291
NDC Product Code 65162-795; 51407-270; 63850-4826; 68180-391; 65162-794; 42292-043; 0378-2246; 68554-0034; 43598-344; 51407-269; 42292-044; 48087-0143; 43598-345; 0378-2245; 68180-390
Synonyms Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Chemical Information
Molecular Formula C29H31N7O
CAS Registry Number 152459-95-5
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chronic myeloid leukaemiaLeptinP41159T7948525648025
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.015985%Not Available
Abdominal distension07.01.04.0010.008259%
Abdominal pain07.01.05.0020.017050%
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.0030.014386%
Abnormal faeces07.01.03.0010.000533%Not Available
Abortion missed18.01.01.0020.000533%Not Available
Abortion spontaneous18.01.04.0010.005861%Not Available
Abscess11.01.08.0010.001865%Not Available
Acne23.02.01.001--Not Available
Activated partial thromboplastin time prolonged13.01.02.0010.000139%
Acute febrile neutrophilic dermatosis23.03.03.033; Available
Acute hepatic failure09.01.03.0010.000486%Not Available
Acute leukaemia16.01.02.001; Available
Acute lymphocytic leukaemia16.01.01.001; Available
Acute myeloid leukaemia16.01.05.001; Available
Acute myocardial infarction24.04.04.001; Available
Acute promyelocytic leukaemia01.10.05.003; Available
Acute respiratory distress syndrome22.01.03.0010.000834%
Acute respiratory failure22.02.06.001; Available
Adenocarcinoma16.16.01.0040.000208%Not Available
Ageusia17.02.07.001; Available
Agranulocytosis01.02.03.0010.001865%Not Available
Alanine aminotransferase increased13.03.01.003--
Ammonia increased13.03.01.0230.000139%Not Available
Amylase increased13.05.01.009--
Amyotrophic lateral sclerosis17.05.05.0040.000556%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 38 Pages